Predictors of Clinically Relevant Change in Management Recommendations After Evaluation of Bone Lesions by 18F-FDG PET Plus ceCT Instead of BS Plus ceCT
| Univariable analysis | |||||
| Predictor | Same treatment, n = 86 (84.3%) | Difference in treatment, n = 16 (15.7%)* | P | AUC | 95% CI |
| Ductal histology of primary tumor (n) | |||||
| No | 16 (88.9%) | 2 (11.1%) | 0.73 | 0.53 | 0.44–0.62 |
| Yes | 70 (83.3%) | 14 (16.7%) | |||
| Hormone receptor status of primary tumor (n) | |||||
| Negative | 12 (70.6%) | 5 (29.4%) | 0.14 | 0.59 | 0.46–0.71 |
| Positive | 74 (87.1%) | 11 (12.9%) | |||
| HER2 status of primary tumor (n) | |||||
| Negative | 67 (85.9%) | 11 (14.1%) | 0.52 | 0.55 | 0.42–0.67 |
| Positive | 19 (79.2%) | 5 (20.8%) | |||
| Grade of primary tumor (n) | |||||
| Grade 1 or 2 | 57 (85.1%) | 10 (14.9%) | 0.77 | 0.53 | 0.39–0.66 |
| Grade 3 | 27 (81.8%) | 6 (18.2%) | |||
| Suspicion of bone metastases (n) | |||||
| No | 63 (85.1%) | 11 (14.9%) | 0.76 | 0.52 | 0.40–0.65 |
| Yes | 23 (82.1%) | 5 (17.9%) | |||
| Relapse time (y) | 0.70 | 0.53 | 0.37–0.69 | ||
| Median | 6 | 7 | |||
| 25th–75th percentiles | 2%–9% | 4%–10% | |||
| Bone lesions on CT (n) | 0.018 | 0.68 | 0.58–0.79 | ||
| Median | 4 | 1 | |||
| 25th–75th percentiles | 0%–20% | 0%–1% | |||
↵* For this analysis of potential predictors of management recommendations based on 18F-FDG PET, 16 patients were included. Patient with changed recommendations based on BS was not included.
AUC = area under receiver-operating-characteristic curve.